Pfizer Pharmaceuticals Korea’s ‘Xalkori’ extended in insurance benefit from this January
Pfizer Pharmaceuticals Korea(CEO/President Dong-Wook Oh) announced its targeted therapy for lung cancer, ‘Xalkori(generic name: crizotinib),’ will be applied by the health insurance benefit as a primary treatment of anaplastic lymphoma kinase(ALK)-positive local-progressive or metastatic non-smal...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
